Trials explorer

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC is being studied. Conditions: KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor • Eligibility: Inclusion Criteria: 1. According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with locally advanced (stage III B/III C), metastatic or recurrent (stage…. Goal: Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V +12 • Eligibility: Inclusion Criteria: * Has at least 1 of the 7 KRAS/NRAS mutated alleles (G12D, G12R, G12V, G12A, G12C, G12S, G13D) * The following must be met: (1) the…. Goal: This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in patients with KRAS/NRAS-mutated pancreatic ductal adenocarcinoma who are at high risk for relapse (ie, presence of isolated tumor cells in a patient whose primary tumor has been removed and is currently without clinical signs of disease). This protocol builds on the experience being obtained with ELI-002 7P (with Amph-Peptides G12D, G12R, G12V, G12A, G12C, G12S, G13D), which is being studied in protocol ELI-002-201. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Elicio Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LY4066434, a pan-KRAS inhibitor, in people with KRAS-mutant solid tumors. - It includes patients whose tumors have specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) and who have locally advanced, unresectable, or metastatic cancer with measurable disease. - The trial will evaluate LY4066434 alone or with other treatments to see if it is safe and tolerable, using two parts: monotherapy dose escalation and dose optimization, over up to about 5 years. - Key exclusions include active CNS metastases, significant cardiovascular disease, active hepatitis B or C or untreated HIV, other active cancers, and uncontrolled infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers is being studied. Conditions: Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: 1. Part A: Histological or cytological proof of advanced KRASm NSCLC, CRC or PDAC; PART B: Histological or cytological proof of advanced KRASm PDAC. 2. Age…. Goal: This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied. Phase/Status/Sponsor: Unknown phase; TERMINATED; The Netherlands Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer is being studied. Conditions: Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation • Eligibility: Inclusion Criteria: * Histologically confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a confirmed KRAS mutation as determined by local results (Part 2) *…. Goal: Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Taiho Oncology, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer is being studied. Conditions: KRAS Mutant Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: Each patient MUST: * Have histologically confirmed cancer of the colon or rectum with radiologically documented and measurable metastases (high CEA alone is insufficient for study…. Goal: This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab. Phase/Status/Sponsor: Unknown phase; COMPLETED; Oncolytics Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) is being studied. Conditions: Solid Tumors, KRAS Mutation • Eligibility: Inclusion Criteria: * Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening. Activating mutations may include but are not…. Goal: This is a study in adults with advanced cancer (solid tumours including non-small cell lung cancer and colorectal cancer) in whom previous chemotherapy was not successful. People who have a tumour with a KRAS mutation can participate in the study. Phase/Status/Sponsor: Unknown phase; TERMINATED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) is being studied. Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma +3 • Eligibility: Inclusion Criteria: * Participants must be assigned to S1900E. Assignment to S1900E is determined by the LUNGMAP protocol genomic profiling using the FoundationOne assay. Biomarker eligibility for S1900E…. Goal: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer is being studied. Conditions: Metastatic Pancreatic Cancer • Eligibility: Inclusion Criteria: * Voluntarily participate in the study and sign the informed consent form. * Male or female aged 18-80 years (inclusive) at the time of signing the…. Goal: This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fluorouracil or gemcitabine, and either progressed on or were intolerant to the last treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Genfleet Therapeutics (Shanghai) Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically verified colorectal adenocarcinomas * Age \> 18 years and \< 70 * Metastatic colorectal cancer refractory 5-FU, oxaliplatin and irinotecan containing treatment regimes *…. Goal: The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vejle Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations is being studied. Conditions: Cholangiocarcinoma • Eligibility: Inclusion Criteria: * Histologically verified adenocarcinoma arisen from gall bladder, extra- or intrahepatic bile ducts or malignant cells consistent with the above and simultaneous radiologic findings consistent with…. Goal: The purpose of this study is to determine the rate of progression free survival of patients with inoperable cholangiocarcinoma 6 months after enrollment in the study. The patients are treated with combination chemotherapy supplemented by biological agents panitumumab or bevacizumab. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vejle Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests a personalized T-cell therapy that uses a patient’s own T cells engineered to recognize KRAS G12D, KRAS G12V, or TP53 R175H mutations in gastrointestinal cancers. - It is for adults aged 18 to 72 who have GI cancers treated with standard therapy and now show signs of occult disease (such as detectable ctDNA or elevated CA19-9) and have the required HLA types. - The trial aims to learn whether this TCR T-cell therapy can prevent or delay recurrence compared with no experimental therapy. - The study is currently withdrawn; key exclusions include evidence of residual or measurable disease, active infections, and certain cardiac or pulmonary conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * informed consent to study procedures, male or female， 18-80 years old. * Histologically or cytologically proven diagnosis of unresectable metastatic colorectal cancer * Patients were…. Goal: To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab is being studied. Conditions: Efficacy • Eligibility: Inclusion Criteria: * Patients who have consented to participate in the KOSMOS-II observational master study. * Age of 19 years or older. * Histologically confirmed locally advanced or…. Goal: Kirsten rat sarcoma (KRAS) mutation is one of the most common genetic mutations associated with tumor development in various human cancers, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Previous studies have shown that KRAS mutations are present in approximately 70% of pancreatic cancer patients, 35% of colorectal cancer patients, 20% of non-small cell lung cancer patients, and 15% of cervical cancer patients. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Korea University Anam Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests mutation analysis and copy number changes of the KRAS and BRAF genes in biliary tract adenocarcinoma. It is for Taiwanese patients diagnosed with biliary tract adenocarcinoma. The study aims to learn whether copy number changes in KRAS or BRAF are a key feature of these tumors in this population. Eligibility includes patients diagnosed with biliary tract adenocarcinoma; no exclusions are listed. The trial status and phase are unknown, and the sponsor is Far Eastern Memorial Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human study of VVD-159642, a RAS-PI3Kα inhibitor, in adults with advanced solid tumors. It aims to evaluate safety and tolerability, plus how the drug behaves in the body (PK/PD), and to see any early anti-tumor activity, both by itself and in combination with sotorasib or trametinib. Eligible participants include people with pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, or any solid tumor with RAS alterations (KRAS, NRAS, HRAS), or with EGFR alterations or HER2 overexpression. Key exclusions include active CNS cancers, significant cardiac disease, uncontrolled hypertension, inflammatory bowel disease or malabsorption issues, and active hepatitis B or C infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC is being studied. Conditions: Colon Cancer • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed colorectal adenocarcinoma, with unresectable metastatic or locally advanced disease documented on diagnostic imaging studies. 2. Previously received 1-2 prior lines of…. Goal: To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Man or woman \> 18 years \< 75 of age * Competent to comprehend, sign, and date an IEC-approved informed consent form * Histologically confirmed…. Goal: The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases. Phase/Status/Sponsor: Unknown phase; COMPLETED; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies is being studied. Conditions: Gastrointestinal Cancer • Eligibility: Inclusion Criteria: 1. Histological or pathological confirmation of malignancy with a KRAS-activating mutation. 2. Extent of disease Advanced disease for which no curable options are available. Subjects who…. Goal: This research study is for patients with an advanced cancer that carries a mutation in a gene called KRAS. Genes are parts of our DNA which carry instructions for a cell (the smallest component of an body part). Phase/Status/Sponsor: Unknown phase; TERMINATED; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer is being studied. Conditions: Colon Cancer, Rectal Cancer • Eligibility: Inclusion Criteria: * Patient must have metastatic colorectal cancer that has been histologically or cytologically-confirmed at MSKCC and has failed to respond to appropriate standard therapy regimens. There…. Goal: The purpose of this study is to test a new drug called MK-2206 for metastatic colorectal cancer. This drug is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in certain genes that may make them more likely to respond to this new medication. Phase/Status/Sponsor: Unknown phase; TERMINATED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Adult Solid Tumor, Adult Disease +5 • Eligibility: Inclusion Criteria: * Males and nonpregnant and non-breastfeeding females, aged ≥ 18 years of age at the time of signing the informed consent. * Subjects with advanced solid…. Goal: The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TOLREMO therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma is being studied. Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant +4 • Eligibility: Inclusion Criteria: * Patients must have histologically, molecularly, or cytologically confirmed recurrent astrocytic tumors including: * GBM or variants, IDH-wildtype, grade 2-4 (standard curative measures available or not)…. Goal: This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) +1 • Eligibility: Inclusion Criteria: * Must be ≥18 years of age * Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or…. Goal: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immuneering Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria: * Signed written Informed Consent. * Male and female subjects aged greater than or equal to18 years. * Eastern Cooperative Oncology Group (ECOG) Performance Score 0…. Goal: This study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \[LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participants may undergo a pre-screening biopsy procedure to determine expression of LGR5. Phase/Status/Sponsor: Unknown phase; RECRUITING; Carina Biotech Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of IK-595 in RAS- or RAF-altered Advanced Tumors is being studied. Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: 1. Patients ≥ 18 years of age. 2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 3. Adequate organ function as…. Goal: This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit. Phase/Status/Sponsor: Unknown phase; TERMINATED; Ikena Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma is being studied. Conditions: Pancreatic Adenocarcinoma Metastatic • Eligibility: Inclusion Criteria: 1. Capable of giving signed informed consent. 2. Male and female participant aged 18 years and older. 3. Participants must have histologically or cytologically confirmed PDAC:…. Goal: This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will be conducted in two parts (Part 1 and Part 2). Phase/Status/Sponsor: Unknown phase; RECRUITING; Oncomatryx Biopharma S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer is being studied. Conditions: BRAF V600 Colorectal Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years * Histologically confirmed metastatic colorectal adenocarcinoma * BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or…. Goal: The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it aims to answer are: Does IB-FOLFIRI improve clinical outcomes compared with historical outcomes in this population? Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases is being studied. Conditions: Brain Metastases, Tumor • Eligibility: Inclusion Criteria: Patients are eligible to be included in the study only if all the following criteria apply: 1. Male/female patients who are at least 18 years of…. Goal: This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in…. Goal: This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; L & L Bio Co., Ltd., Ningbo, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must…. Goal: The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic Ultrasound is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: * Age: 18 years old or older * Diagnosis: CT, MRI, transabdominal ultrasound or other imaging examinations showed a pancreatic mass, and 3 endoscopists agreed on…. Goal: The goal of this clinical trial is to learn about the feasibility of collecting pancreatic juice through duodenal aspiration by ultrasound endoscopy (EUS) for molecular marker testing after intraduodenal infusion of vinegar in patients with suspected pancreatic cancer and who are scheduled to have endoscopic ultrasound with fine needle aspiration (EUS-FNA). The main questions it aims to answer are: * Is vinegar-induced collection of duodenal pancreatic juice via endoscopic ultrasound feasible? Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers is being studied. Conditions: Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor • Eligibility: Inclusion Criteria: Molecular Pre-screening Inclusion criteria 1. cMET amplification in tumor sample; OR 2. cMET overexpression in tumor sample; OR 3. EGFR overexpression in tumor sample; OR 4.…. Goal: This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai EpimAb Biotherapeutics Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: A. Unresectable Pancreatic Cancer: 1. At least 20 years of age at the time of consent 2. Histopathologically confirmed adenocarcinoma and diagnosed as having ① or…. Goal: This is a multicenter, prospective, observational study to evaluate the utility of the Invitae Personalized Cancer MonitoringTM assay for patients with resectable and unresectable pancreatic cancer. Using tumor tissue, a personalized blood test (the Invitae Personalized Cancer MonitoringTM test) will be developed that can be used for repeated monitoring to assess for the presence or absence of circulating tumor DNA (ctDNA). Phase/Status/Sponsor: Unknown phase; RECRUITING; Invitae Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy 2. Age≥ 18 3. ECOG PS:0-1 4. Tumor molecular testing…. Goal: The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Female patients with pretreated epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer with histological confirmation of the tumor * Wild-type k-ras status *…. Goal: The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with carboplatin and either pegylated liposomal doxorubicin or gemcitabine) in relation to the respective standard combination in patients with a KRAS wildtype with platinum-sensitive recurrent ovarian cancer. It is expected that the progression free survival rate at 12 months is improved by the targeted regimen. Phase/Status/Sponsor: Unknown phase; UNKNOWN; WiSP Wissenschaftlicher Service Pharma GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care is being studied. Conditions: NSCLC, Melanoma • Eligibility: Inclusion Criteria To participate in this study a participant must meet the eligibility of one of the following cohorts: Cohort 1: Cancers beginning initial treatment * One of…. Goal: Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. voluntarily sign a written informed consent to participate in the study and be willing and able to comply with study-related visits and procedures; 2. Male…. Goal: The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are: * If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation * If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation Participants will 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Pearl Biotechnology Limited Liability Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) is being studied. Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer) *…. Goal: This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mirati Therapeutics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an electrocardiogram (ECG)…. Goal: This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE is being studied. Conditions: Rectum Cancer • Eligibility: Inclusion Criteria: 1. Patients over 18 years old suffering from cancer of the lower ampullary rectum cT1-T4N0-2M0 (according to the classification of malignant tumors TNM in the 8th…. Goal: A multicenter, cohort, randomized, controlled study is being conducted since the 1of September, 2023 whereby the immediate and long-term results of pelvic floor and perineal wound plastic surgery after extralevatory abdominal-perineal extirpation of the rectum will be compared. The study is conducted on the basis of the Federal State Budgetary Educational Institution of the Ministry of Health Care of the Russian Federation, the Department of General Surgery at the clinical base of the State Budgetary Healthcare Institution " Krasnodar Regional Hospital No. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Kuban State Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Selumetinib and Olaparib in Solid Tumors is being studied. Conditions: Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs +2 • Eligibility: Inclusion Criteria: 1. Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. 2. Age \>/= 18 years at time of study…. Goal: This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given to patients who have solid tumors that are advanced or recurrent (has returned after treatment). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Participants with surgically unresectable locally advanced or metastatic disease who have received one prior line of chemotherapy. (The Phase 1 portion of the study will…. Goal: ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the safety, tolerability, and efficacy of ARQ 197, define the recommended dose for Phase 2. After the recommended dose is determined for Phase 2, participants receive study drug or placebo with irinotecan and cetuximab. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an AKT mutation…. Goal: This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have a PIK3CA mutation…. Goal: This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) is being studied. Conditions: Malignant Solid Neoplasm • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol * Patients must fulfill all…. Goal: The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer is being studied. Conditions: Colon Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with KRASG12C mutation. KRASG12C on ctDNA may also be used as basis of eligibility, with…. Goal: To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Treatment of Colon Cancer is being studied. Conditions: Colon Cancer • Eligibility: Inclusion Criteria: * Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan * Analysis of KRAS, BRAF, PIK3CA * Age ≥18 år * Performance…. Goal: This study will investigate * the effect of preoperative combination chemotherapy in patients with locally advanced colon cancer with mutation in the KRAS, BRAF or PIK3CA gene * the effect of preoperative combination chemotherapy in combination with biological treatment in patients without mutation in the KRAS, BRAF or PIK3CA gene. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vejle Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients is being studied. Conditions: Non-squamous Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. The participant voluntarily joins this clinical research study, understands the research procedures, and is capable of providing written informed consent by signing the Informed Consent…. Goal: Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Shengdi Pharmaceutical Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors is being studied. Conditions: Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma +2 • Eligibility: Inclusion Criteria: * Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent. * Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor…. Goal: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer is being studied. Conditions: Advanced/Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Subjects voluntarily sign informed consent * Age: from 18 to 70 years old * Definite histological evidence of colorectal adenocarcinoma * ECOG 0-1 * Advanced…. Goal: This is an prospective, single-center, single-arm, Simon's two-stage design, phase IIa study for advanced/metastatic colorectal cancer (CRC) who had failed or were intolerant to standard treatment. This study aims to evaluate the safety and efficacy of mFOLFOX6 combined with dalpiciclib (SHR6390) in the treatment of advanced/metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sixth Affiliated Hospital, Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients is being studied. Conditions: Fruquintinib, Irinotecan, Capecitabine +1 • Eligibility: Inclusion Criteria: 1. Subjects voluntarily enrolled in the study and signed an informed consent form, were compliant and cooperated with follow-up visits; 2. Patients with metastatic colorectal adenocarcinoma…. Goal: This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; China Medical University, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: 1. Age between 18 and 75 years inclusive; 2. Histologically or cytologically confirmed advanced malignant solid tumors, eligible patients should be either refractory or intolerant to…. Goal: The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Nanjing Sanhome Pharmaceutical, Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC is being studied. Conditions: Carcinoma, Non-Small-Cell Lung, Docetaxel, Nivolumab • Eligibility: Inclusion Criteria: 1. Men \& women ≥18, and ≤75 years of age. 2. Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or…. Goal: This study is a randomized, single-center, open-label, phase II clinical trial designed to evaluate non-small cell lung cancer that has failed to undergo excessive platinum-based chemotherapy and has not received excessive statin chemotherapy and has not received immunotherapy. The efficacy and safety of Nivolumab in combination with docetaxel and Nivolumab in patients. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Peking University Cancer Hospital & Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy is being studied. Conditions: Metastatic Colorectal Cancer, Pancreas Adenocarcinoma, Cholangiocarcinoma • Eligibility: Inclusion Criteria: Newly referred patients with advanced pancreatic cancer (\~20/year), Cholangiocarcinoma (\~20/year), metastatic colorectal cancer (mCRC) (\~50/year) and anti-EGFR-treated mCRC patients (\~10/year) to Oslo University Hospital are eligible…. Goal: Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid biopsies relevant in advanced gastrointestinal malignancies with focus on clinical utility and sensible use of resources. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) is being studied. Conditions: Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma +1 • Eligibility: Inclusion Criteria: 1. The subjects voluntarily sign the written informed consent form and can comply with the visits and related procedures specified in the protocol; 2. The subjects…. Goal: Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging. Previous genomic profiling studies showed they presented a number of somatic mutations. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Jiao Tong University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ZW25 (zanidatamab) added to standard first-line chemotherapy in people with HER2-expressing gastrointestinal cancers that are unresectable or metastatic, specifically gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer. The study has two parts: Part 1 checks safety and tolerability and helps establish a recommended dose for the combination, and Part 2 evaluates the anti-tumor activity. Eligible participants have HER2-expressing tumors, are unresectable or metastatic, and have good performance status with adequate organ and heart function; colorectal cancer participants must have wild-type RAS/BRAF, with additional biomarker criteria by part. Key exclusions include prior HER2-targeted therapy, recent systemic cancer treatment (with limited exceptions), untreated brain metastases, significant cardiac disease, QTc prolongation, active infections, or uncontrolled HIV/HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically proven diagnosis of colorectal adenocarcinoma; * Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease; * At least one measurable…. Goal: The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab as first line treatment of patients with initially unresectable and previously untreated RAS wild-type metastatic colorectal cancer (mCRC), in terms of Progression-free Survival. Phase/Status/Sponsor: Unknown phase; COMPLETED; Gruppo Oncologico del Nord-Ovest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases is being studied. Conditions: Colorectal Neoplasms • Eligibility: Inclusion Criteria: 1. Histologically confirmed metastatic adenocarcinoma of the colon or rectum. 2. Patients who have been previously treated with or are not candidates for fluorouracil, oxaliplatin, irinotecan,…. Goal: The purpose of this study is to determine the safety of regorafenib, an antiangiogenic drug, when combined with radioembolization using SIR-Spheres® microspheres in the treatment of colorectal cancer (CRC) that has spread to the liver. Phase/Status/Sponsor: Unknown phase; COMPLETED; SCRI Development Innovations, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Investigator and subinvestigator judge a candidate is understand clinical trial and comply this protocol. Investigator is those who participate in conducting a study and oversight…. Goal: The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Takeda.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer is being studied. Conditions: Malignant Neoplasms of Digestive Organs, Colorectal Cancer, Colon Cancer • Eligibility: Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed metastatic colorectal cancer. 2. Patients must have measurable disease per RECIST v1.1 criteria. 3. Patients must have had…. Goal: The goal of this clinical research study is to learn if durvalumab and trametinib can help to control microsatellite stable (MSS) colorectal cancer. The safety of these drugs will also be studied. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * 1\. Female or male patients with at least 18 years at the time the informed consent is signed * 2.ECOG (Eastern Cooperative Oncology Group)performance status…. Goal: The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to correlate this response with patient's outcome. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PiCCA study, now completed, tested whether adding panitumumab to Cisplatin/Gemcitabine helps adults with biliary tract cancers as first-line treatment. It enrolled patients with KRAS wild-type cholangiocarcinoma or gallbladder carcinoma whose disease was unresectable or metastatic and who had measurable disease. The goal was to learn whether the combination improves outcomes compared with historical data or with the same chemotherapy alone without the antibody. Key exclusions included KRAS mutation, brain metastases, significant cardiovascular disease, interstitial lung disease, active infections, and prior anti-EGFR therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer +3 • Eligibility: Inclusion Criteria: * Only advanced carcinomas defined as unresectable or metastatic that are histologically or cytologically confirmed to be biliary tract, pancreas, duodenal, or ampullary carcinomas will be…. Goal: RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vanderbilt-Ingram Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Erlotinib in Combination With Pralatrexate in Advanced Malignancies is being studied. Conditions: Advanced Cancers, Solid Tumors • Eligibility: Inclusion Criteria: 1. Measurable or non-measurable disease. 2. Patients with advanced cancer should be refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that…. Goal: The goal of this clinical research study is to find the highest tolerable dose of the combination of erlotinib and pralatrexate that can be given to patients with advanced cancer. The safety of the drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer is being studied. Conditions: Extrahepatic Bile Duct Cancer, Pancreatic Cancer • Eligibility: DISEASE CHARACTERISTICS: * Serum samples available from participants meeting any of the following criteria: * Diagnosis of pancreatic or extrahepatic biliary tract cancer * Suspected of having pancreatic…. Goal: RATIONALE: Studying samples of blood in the laboratory from patients with cancer and from healthy participants may help doctors identify and learn more about proteins related to cancer. It may also help doctors tell whether a patient has cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer is being studied. Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7 +6 • Eligibility: Inclusion Criteria: * Histological or cytological documentation of adenocarcinoma of the colon or rectum * Advanced or metastatic colorectal cancer with no curative options available and progression on…. Goal: This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Academic and Community Cancer Research United.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors is being studied. Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer +9 • Eligibility: Inclusion Criteria: 1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA…. Goal: A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors Phase/Status/Sponsor: Unknown phase; TERMINATED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LB4330, a fusion protein that targets Claudin 18.2 and activates CD8 T cells, to see if it is safe and tolerable in people with advanced solid tumors. - It is a first-in-human, open-label Phase I trial given by IV, with a dose-escalation part and a dose-expansion part. - Participants are adults aged 18-75 with advanced solid tumors; some cohorts require Claudin 18.2 expression while others do not, depending on the cohort. - The trial aims to learn about safety, tolerability, pharmacokinetics, and immunogenicity of LB4330. - Key exclusions include recent systemic cancer therapy, active infection, autoimmune disease, brain metastases needing steroids, and significant cardiovascular or liver/kidney problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer • Eligibility: Inclusion Criteria: 1. Histologically confirmed pancreatic ductal adenocarcinoma with unequivocal first progression after surgery followed by chemotherapy 2. Without any immunotherapy or targeted therapy 3. A life expectancy…. Goal: Hypothesis: Survival benefits could be found in SBRT Plus Pembrolizumab and Trametinib compared with SBRT plus gemcitabine. Phase/Status/Sponsor: Unknown phase; COMPLETED; Changhai Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tested the drug selumetinib in people with biliary tract cancer that cannot be removed by surgery. - It aimed to see how well selumetinib could shrink tumors and to assess safety, survival, and progression-free survival. - Researchers also looked for biomarkers in tumor tissue, focusing on mutations and activity in the RAS/RAF/MEK/ERK pathway to see if these relate to treatment benefit. - Eligible participants were adults with unresectable biliary cancer, measurable disease, and adequate organ function, while key exclusions included prior sorafenib or other MEK inhibitors, pregnancy, brain metastases, and other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Evaluable or measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of ≥12 weeks…. Goal: The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage. Phase/Status/Sponsor: Unknown phase; COMPLETED; Genentech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China is being studied. Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma +4 • Eligibility: Inclusion Criteria: 1. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status score…. Goal: This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. Phase/Status/Sponsor: Unknown phase; COMPLETED; Allist Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies is being studied. Conditions: Advanced Solid Tumors, Cancer, Hematologic Malignancies • Eligibility: Inclusion Criteria: * Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any…. Goal: This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment. Phase/Status/Sponsor: Unknown phase; COMPLETED; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biomarker Directed Treatment in Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1.1 Inclusion criteria for pre-screening phase: * Untreated advanced metastatic colorectal cancer patients * Adequate tissue to evaluate for genotyping (10 x 10µm thick formalin fixed…. Goal: This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with either FOLFOX or FOLFIRI in combination with cetuximab the median response rate is approximately 60-65%. Phase/Status/Sponsor: Unknown phase; COMPLETED; Arbeitsgemeinschaft medikamentoese Tumortherapie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers is being studied. Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic • Eligibility: Inclusion Criteria: * The subject provides written informed consent. * Adults ≥ 18 years of age on day of signing informed consent. * Disease must be measurable per…. Goal: SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; TERMINATED; SignalChem Lifesciences Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma is being studied. Conditions: Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Patients must have histological or cytological confirmed melanoma that is metastatic or unresectable stage IIIc and clearly progressive. 2. Patients must have melanoma that is…. Goal: This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF antibody that suppresses new blood vessel formation and can stimulate the immune system. Previous clinical studies in melanoma have shown that bevacizumab may improve clinical benefit (progression free survival) if combined with ipilimumab or abraxane. Phase/Status/Sponsor: Unknown phase; TERMINATED; Melanoma Research Foundation Breakthrough Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment is being studied. Conditions: Colorectal Carcinoma • Eligibility: Inclusion Criteria: 1. Patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS who are planned to receive treatment with panitumumab monotherapy after failure of fluoropyrimidine-,…. Goal: Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Phase/Status/Sponsor: Unknown phase; TERMINATED; Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) is being studied. Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer • Eligibility: Inclusion Criteria: * Willingness to provide written informed consent for the study. * Willingness to undergo a pretreatment and on-treatment tumor biopsy to obtain tumor tissue. * Eastern…. Goal: This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination. Phase/Status/Sponsor: Unknown phase; TERMINATED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC is being studied. Conditions: Metastatic Colorectal Cancer (mCRC) • Eligibility: Inclusion Criteria: 1. Age 18-75 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 3. Life expectancy ≥ 6 months 4. Histologically confirmed colorectal…. Goal: This trial is conducted in patients with the recurrent lesion(s) post-surgery or the untreated mCRC. After stratification with respect to ECOG PS score, chemo regimen, primary tumor location and KRAS and BRAF genotype (complete wild-type/primal type), eligible patients are randomized into two arms at 1:1 ratio to receive HLX04 (Arm A) or Bevacizumab (Arm B) in combination with one of the protocol-defined chemotherapies, modified FOLFOX6 (mFOLFOX6) or XELOX for mCRC until disease progression (PD) or unacceptable toxicity or achieving an operable contingency, whichever occurs first. Phase/Status/Sponsor: Unknown phase; COMPLETED; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests afatinib, a pan-ERBB inhibitor, in people with advanced cancers that have NRG1 gene rearrangements after standard therapy has not worked. - There are separate arms for KRAS wild-type pancreatic cancer and invasive mucinous adenocarcinoma, plus a third arm for other NRG1-rearranged tumors. - The study aims to learn how effective afatinib is against these tumors and to explore mechanisms of resistance, including using blood tests (liquid biopsies) to monitor changes. - Key exclusions include prior afatinib treatment, active brain metastases unless treated and stable, interstitial lung disease, pregnancy or inability to use effective contraception. - Status: COMPLETED.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients is being studied. Conditions: Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria: * Patients with a histologically confirmed diagnosis of mCRC. * Immunohistochemical evidence of EGFR expression. * ECOG performance status of 0, 1 or 2. * Patients…. Goal: This is a phase IV multicenter trial to evaluate real-world health outcomes, economic impact and resistance mechanisms of panitumumab in the treatment of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). This study will address two anticipated issues surrounding personalized medicine and treatment with panitumumab. Phase/Status/Sponsor: Unknown phase; COMPLETED; PeriPharm.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tested whether bile samples can reveal the tumor mutation profile and genotype in people with malignant biliary strictures (cholangiocarcinoma or cancer of the head of the pancreas). It also looked at whether levels of VEGF and MMPs in bile could help diagnose these conditions. For tumor genotyping, 10 adults who were surgically treated for malignant biliary stricture with confirmed cancer were included; for biomarkers, bile collected during ERCP from 100 adults (50 malignant, 50 benign) was analyzed. Eligible participants were adults who consented to storage of bile and tissue in the hospital tissue bank; those who did not consent were excluded. The trial is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Neoplasms • Eligibility: Inclusion criteria: 1. Patients with metastatic colorectal cancer who have failed both oxaliplatin- and irinotecan-based regimens 2. Tumour sample available for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene…. Goal: This Phase II study is open to patients with metastatic colorectal cancer who have tried but failed chemotherapy regimens containing oxaliplatin and irinotecan. Patients must not have received anti-EGFR (Epidermal Growth Factor Receptor) treatment (for example, cetuximab, panitumumab) in the past. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Adult male and female subjects aged 18-80 years at screening visit 2. Pathologically confirmed diagnosis of MSS/pMMR colorectal adenocarcinoma 3. Presenting with metastatic disease: *…. Goal: Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga (regorafenib) or Fruzaqla (fruquintinib) combining experimental AlloStim with an anti-programmed death ligand 1 (PD-L1) checkpoint inhibitor drug. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Mirror Biologics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery is being studied. Conditions: Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum +6 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed adenocarcinoma arising from the large intestine that has metastasized to the liver; liver metastases may be synchronous or metachronous *…. Goal: This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer +1 • Eligibility: Inclusion Criteria: * Age ≥ 18 years with a recurrent solid tumor in the Phase I portion of the trial or in the Phase II portion of the…. Goal: The purpose of the first part of this study or the dose escalation portion of the study is to determine what dose of BKM120 and Abraxane is safe to give when the two drugs are used at the same time in patients who are diagnosed with a solid cancer. A solid cancer is a cancer that does not involve the blood, bone marrow or lymph nodes. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer is being studied. Conditions: Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of mCRC * RAS wild-type status (by a Clinical Laboratory Improvement Amendments \[CLIA\] certified assay that includes all known mutations…. Goal: This phase I trial studies the side effects and the best dose of irinotecan hydrochloride, based on a genetic test, when given in combination with fluorouracil, leucovorin calcium, and cetuximab as first-line therapy in treating patients with an abnormal gene called RAS wild-type that has spread to other parts of the body (metastatic). Patients may also have a gene called uridine diphosphate glucuronosyltransferase (UGT1A1) that may interfere with the way irinotecan hydrochloride is absorbed by the body and may not be able to tolerate it. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis is being studied. Conditions: Colon Cancer • Eligibility: Inclusion Criteria: * Adenocarcinomas of the colon (C18) and rectosigmoid junction (C19) * Resident in Côte-d'Or * Treated by surgical resection Exclusion Criteria: * Rectal cancer * Cancer…. Goal: We conducted a preliminary study in 2010 using the innovative Illumina GoldenGate (methylation assay) which has enabled us to characterize the level of methylation of 807 potential markers on a series of 200 adenocarcinomas of the colon (C18) and rectosigmoid junction (C19) resected between 1998 and 2001. The results, validated by pyrosequencing, allowed us to establish a panel of 12 markers to assess the level of methylation. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Centre Hospitalier Universitaire Dijon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.